Potential Biomarker for Reduction of Viral Load Identified for Vacc-4x
Exploratory, ad hoc, subset analysis of previous large Vacc-4x Phase II study identifies patients more likely to respond to Vacc-4x (“Responders”) (Oslo, Norway, 4 February 2014) Bionor Pharma ASA (OSE: BIONOR) announces that further analysis of the large Vacc-4x Phase II trial, completed in 2010, identified anti-C5 antibodies as potential biomarker for the Company’s lead …
Poster presentation of Reboost Phase II study with Vacc-4x at GLOBVAC conference
Step towards long lasting HIV viral control with repeated Vacc-4x immunizations (Bergen, Norway, 16 October 2013) Bionor Pharma ASA (OSE: BIONOR) is today giving a poster presentation of the Reboost Phase II study with Vacc-4x, which received a grant from GLOBVAC in 2012, at the GLOBVAC conference in Bergen. The poster is entitled “Towards Eradication …
Bionor Pharma’s “Kick, Kill & Boost” Strategy Advances – Romidepsin Chosen as the “Kick”
Oslo 10.09.2013 – Bionor Pharma ASA (OSE: BIONOR) announces that the Company has chosen romidepsin for the planned combination study with Vacc-4x, after considering various HDAC inhibitors (HDACi). Romidepsin is marketed in the US as Istodax® by Celgene Corporation Inc. The “Kick, Kill” study is planned to be conducted by the HIV research team at …
Analysis of Immune Responses in Patients Treated with Vacc-4x Supports Further Development
Boston 12.09.2012 – Researchers from the Vaccine Immunotherapy Center at the Lausanne University Hospital presented yesterday immunological data from the phase II study with Vacc-4x during an oral session at the AIDS Vaccine 2012 conference in Boston. News Summary • Data from Vacc-4x study presented at the largest and most prestigious global scientific conference focused …
Bionor Pharma’s First Reboost Vacc-4x Study Accepted for Publication in the Vaccine Journal
(Oslo, Norway, 7 August 2013) Bionor Pharma ASA (OSE: BIONOR) announces that the results from the Company’s first re-boost clinical trial of Vacc-4x have been accepted for publication in the renowned journal Vaccine. The Phase II trial was conducted at Oslo University Hospital and completed in 2010. The trial investigated the effect of re-boosting 22 …
HIV research by Danish scientists presented at AIDS conference in Kuala Lumpur, Malaysia
Oslo 01.07.2013 – The study was recently presented by Prof. Lars Østergaard from Aarhus University Hospital at Bionor Pharma’s Capital Markets Day in Oslo, 14 June. See article in the Danish newspaper Berlingske 30 June about the research with HDAC Inhibitors in HIV patients, presented at the conference in Kuala Lumpur: http://www.b.dk/nationalt/dansk-gennembrud-i-kampen-mod-hiv# See also information at …
Bionor Pharma Announces Successful Completion of the First Part of its Phase II Clinical Study Combining the HIV Vaccine Vacc-4x with Celgene’s Immunomodulator Lenalidomide (Revlimid®)
Oslo 13.06.2013 – The highest dose of lenalidomide has been chosen for the second, placebo-controlled part of the study, where a number of HIV patients are ready for screening Bionor Pharma ASA (OSE: BIONOR) announced today that the first part of its phase II clinical study combining the HIV vaccine, Vacc-4x, with Celgene’s immunomodulator, lenalidomide, …
Bionor Pharma Announces Filing of International Patent Application for its HIV Vaccine Vacc-HIV
Oslo, 11.06.2013 – Bionor Pharma ASA (OSE: BIONOR) announced today that it has filed an International Patent Application for its HIV Vaccine, Vacc-HIV. This application gives Bionor Pharma the opportunity to obtain patent protection for Vacc-HIV in all the major international pharmaceutical markets. Vacc-HIV, which is currently in the preclinical stage of development, is a …
Patient Enrollment Completed in Bionor Pharma’s First Human Clinical Study of the HIV Vaccine Vacc-C5
Oslo 27.05.2013 – Bionor Pharma ASA (OSE: BIONOR) announced today that patient enrollment in the first clinical study of its second HIV vaccine, Vacc-C5, is now completed, with 36 HIV infected patients enrolled at Oslo University Hospital. Thirty six HIV Patients Participate at Oslo University Hospital Vacc-C5 has been developed with the aim to induce …
Last Patient Enrolled in Bionor Pharma’s International Study to Reboost Patients from the Completed Vacc-4x Phase II Clinical Trial
Oslo 29.04.2013 – Bionor Pharma ASA (OSE: BIONOR) announced today that all patients are now enrolled in the study for reboost of patients from the previously conducted phase II clinical study with Vacc-4x. Thirty-three Patients Participate at 10 Clinics in USA and Europe The 33 patients are recruited at 10 clinics in USA, Germany, England, …